The reasons for the discrepancy might root in different patient cohorts or different evaluation systems: The group of Hirakawa et al. [22] used a scoring system ranging from 0 (no immunoreaction or immunoreaction in <10% of tumor cells) to 3 (strong immunoreaction in >10% of tumor cells); scores of 2+ and 3+ were considered to be positive for IGF1R overexpression. Here, IGF1R is linked to neoplasm.